CoChat

Silicone Oil Microdroplets Can Induce Antibody Responses Against Recombinant Murine Growth Hormone in Mice

Open access
Chisholm, Carly Fleagle, Baker, Abby E., Soucie, Kaitlin R., Torres, Raul M., Carpenter, John F., Randolph, Theodore W. · 2016 · Journal of Pharmaceutical Sciences
Cited by 40

The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.

Abstract

Therapeutic protein products can cause adverse immune responses in patients. The presence of sub-visible particles is a potential contributing factor to the immunogenicity of parenterally-administered therapeutic protein formulations. Silicone oil microdroplets, which derive from silicone oil used as a lubricating coating on barrels of prefilled glass syringes, are often found in formulations. In this study, we investigated the potential of silicone oil microdroplets to act as adjuvants to induce an immune response in mice against a recombinant murine protein. Antibody responses in mice to subcutaneous injections of formulations of recombinant murine growth hormone (rmGH) that contained silicone oil microdroplets were measured and compared to responses to oil-free rmGH formulations. When rmGH formulations containing silicone oil microdroplets were administered once every other week, anti-rmGH antibodies were not detected. In contrast, mice exhibited a small IgG1 response against rmGH when silicone oil-containing rmGH formulations were administered daily, and an anti-rmGH IgM response was observed at later time points. Our findings showed that silicone oil microdroplets can act as an adjuvant to promote a break in immunological tolerance and induce antibody responses against a recombinant self-protein.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.xphs.2016.02.019

Cites

4 of 4 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 4 references

Research works printed but not linked: 60

  1. Hermeling, 2004, Structure-immunogenicity relationships of therapeutic proteins, Pharm Res, 21, 897, 10.1023/B:PHAM.0000029275.41323.a6 · DOI · Paper page
  2. Carpenter, 2009, Overlooking subvisible particles in therapeutic protein products: gaps that may compromise product quality, J Pharm Sci, 98, 1201, 10.1002/jps.21530 · DOI · Paper page
  3. Biro, 1965, The antigenicity of aggregated and aggregate-free human gamma-globulin for rabbits, Immunology, 8, 411
  4. Christian, 1960, Studies of aggregated gamma-globulin II. Effect in vivo, J Immunol, 84, 117, 10.4049/jimmunol.84.1.117 · DOI
  5. Gamble, 1966, The role of soluble aggregates in the primary immune response of mice to human gamma globulin, Int Arch Allergy Appl Immunol, 30, 446, 10.1159/000229829 · DOI · Paper page
  6. Ring, 1977, Anaphylactoid reactions due to non-immune serum protein aggregates, Monogr Allergy, 12, 27
  7. Weksler, 1970, Immunologic responses of graft recipients to antilymphocyte globulin: effect of prior treatment with aggregate-free gamma globulin, J Clin Invest, 49, 1589, 10.1172/JCI106376 · DOI
  8. Fradkin, 2009, Immunogenicity of aggregates of recombinant human growth hormone in mouse models, J Pharm Sci, 98, 3247, 10.1002/jps.21834 · DOI · Paper page
  9. Joubert, 2012, Highly aggregated antibody therapeutics can enhance the in vitro innate and late-stage T-cell immune responses, J Biol Chem, 287, 25266, 10.1074/jbc.M111.330902 · DOI · Paper page
  10. Ahmadi, 2015, Small amounts of sub-visible aggregates enhance the immunogenic potential of monoclonal antibody therapeutics, Pharm Res, 32, 1383, 10.1007/s11095-014-1541-x · DOI · Paper page
  11. Rombach-Riegraf, 2014, Aggregation of human recombinant monoclonal antibodies influences the capacity of dendritic cells to stimulate adaptive T-cell responses in vitro, PLoS One, 9, 1, 10.1371/journal.pone.0086322 · DOI · Paper page
  12. Tyagi, 2009, IgG particle formation during filling pump operation: a case study of heterogeneous nucleation on stainless steel nanoparticles, J Pharm Sci, 98, 94, 10.1002/jps.21419 · DOI · Paper page
  13. Fradkin, 2011, Glass particles as an adjuvant: a model for adverse immunogenicity of therapeutic proteins, J Pharm Sci, 100, 4953, 10.1002/jps.22683 · DOI
  14. Shomali, 2014, Antibody responses in mice to particles formed from adsorption of a murine monoclonal antibody onto glass microparticles, J Pharm Sci, 103, 78, 10.1002/jps.23772 · DOI
  15. Van Beers, 2012, Immunogenicity of recombinant human interferon beta interacting with particles of glass, metal, and polystyrene, J Pharm Sci, 101, 187, 10.1002/jps.22744 · DOI
  16. Romacker, 2008, The rise of prefilled syringes from niche product to primary container of choice: a short history, ONdrug Deliv, 4
  17. Jezek, 2013, Biopharmaceutical formulations for pre-filled delivery devices, Expert Opin Drug Deliv, 10, 811, 10.1517/17425247.2013.780023 · DOI · Paper page
  18. Cleland, 1993, The development of stable protein formulations: a close look at protein aggregation, deamidation, and oxidation, Crit Rev Ther Drug Carrier Syst, 10, 307
  19. Jenke, 2014, Extractables and leachables considerations for prefilled syringes, Expert Opin Drug Deliv, 11, 1591, 10.1517/17425247.2014.928281 · DOI · Paper page
  20. Gampper, 2007, Silicone gel implants in breast augmentation and reconstruction, Ann Plast Surg, 59, 581, 10.1097/01.sap.0000258970.31562.5d · DOI
  21. Hajdu, 2011, Silicone and autoimmunity, Eur J Clin Invest, 41, 203, 10.1111/j.1365-2362.2010.02389.x · DOI
  22. Chantelau, 1985, Pollution of insulin with silicone oil, a hazard of disposable plastic syringes, Lancet, 1, 1459, 10.1016/S0140-6736(85)91892-6 · DOI
  23. Chantelau, 1986, Silicone oil released from disposable insulin syringes, Diabetes Care, 9, 672, 10.2337/diacare.9.6.672 · DOI
  24. Bernstein, 1987, Clouding and deactivation of clear (regular) human insulin: association with silicone oil from disposable syringes?, Diabetes Care, 10, 786, 10.2337/diacare.10.6.786 · DOI
  25. Ludwig, 2010, Protein adsorption and excipient effects on kinetic stability of silicone oil emulsions, J Pharm Sci, 99, 1721, 10.1002/jps.21982 · DOI
  26. Britt, 2012, Excipient effects on humanized monoclonal antibody interactions with silicone oil emulsions, J Pharm Sci, 101, 4419, 10.1002/jps.23318 · DOI
  27. Gerhardt, 2013, Ionic strength affects tertiary structure and aggregation propensity of a monoclonal antibody adsorbed to silicone oil – water interfaces, J Pharm Sci, 102, 429, 10.1002/jps.23408 · DOI
  28. Thirumangalathu, 2009, Silicone oil- and agitation-induced aggregation of a monoclonal antibody in aqueous solution, J Pharm Sci, 98, 3167, 10.1002/jps.21719 · DOI · Paper page
  29. Basu, 2014, Albinterferon α2b adsorption to silicone oil-water interfaces: effects on protein conformation, aggregation, and subvisible particle formation, J Pharm Sci, 103, 427, 10.1002/jps.23821 · DOI
  30. Jones, 2005, Silicone oil induced aggregation of proteins, J Pharm Sci, 94, 918, 10.1002/jps.20321 · DOI · Paper page
  31. Basu, 2013, IgG1 aggregation and particle formation induced by silicone-water interfaces on siliconized borosilicate glass beads: a model for siliconized primary containers, J Pharm Sci, 102, 852, 10.1002/jps.23434 · DOI
  32. Majumdar, 2011, Evaluation of the effect of syringe surfaces on protein formulations, J Pharm Sci, 100, 2563, 10.1002/jps.22515 · DOI
  33. O’Hagan, 2009, The path to a successful vaccine adjuvant—“the long and winding road”, Drug Discov Today, 14, 541, 10.1016/j.drudis.2009.02.009 · DOI · Paper page
  34. Israeli, 2009, Adjuvants and autoimmunity, Lupus, 18, 1217, 10.1177/0961203309345724 · DOI · Paper page
  35. Naim, 1993, The adjuvant effect of silicone-gel on antibody formation in rats, Immunol Invest, 22, 151, 10.3109/08820139309063397 · DOI · Paper page
  36. Chisholm, 2015, In vivo analysis of the potency of silicone oil microdroplets as immunological adjuvants in protein formulations, J Pharm Sci, 104, 3681, 10.1002/jps.24573 · DOI · Paper page
  37. Shomali, 2015, Dose levels in particulate-containing formulations impact anti-drug antibody responses to murine monoclonal antibody in mice, J Pharm Sci, 104, 1610, 10.1002/jps.24413 · DOI
  38. Schellekens, 2002, Immunogenicity of therapeutic proteins: clinical implications and future prospects, Clin Ther, 24, 1720, 10.1016/S0149-2918(02)80075-3 · DOI · Paper page
  39. Sauerborn, 2010, Immunological mechanism underlying the immune response to recombinant human protein therapeutics, Trends Pharmacol Sci, 31, 53, 10.1016/j.tips.2009.11.001 · DOI · Paper page
  40. Shankar, 2007, A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs, Nat Biotechnol, 25, 555, 10.1038/nbt1303 · DOI · Paper page
  41. Ahangari, 2004, Growth hormone antibodies formation in patients treated with recombinant human growth hormone, Int J Immunopathol Pharmacol, 17, 33, 10.1177/039463200401700105 · DOI
  42. Fineberg, 1983, Immunogenicity of recombinant DNA human insulin, Diabetologia, 25, 465, 10.1007/BF00284452 · DOI · Paper page
  43. Konrad, 1987, Assessment of the antigenic response in humans to a recombinant mutant interferon beta, J Clin Immunol, 7, 365, 10.1007/BF00917014 · DOI
  44. Karmiris, 2009, Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn’s disease, Gastroenterology, 137, 1628, 10.1053/j.gastro.2009.07.062 · DOI · Paper page
  45. Jamnitski, 2011, The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept, Ann Rheum Dis, 70, 284, 10.1136/ard.2010.135111 · DOI · Paper page
  46. Radstake, 2009, Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis, Ann Rheum Dis, 68, 1739, 10.1136/ard.2008.092833 · DOI · Paper page
  47. Nanda, 2013, Impact of antibodies to infliximab on clinical outcomes and serum infliximab levels in patients with inflammatory bowel disease (IBD): a meta-analysis, Am J Gastroenterol, 108, 40, 10.1038/ajg.2012.363 · DOI · Paper page
  48. O’Meara, 2014, Antibodies to infliximab and risk of infusion reactions in patients with inflammatory bowel disease: a systematic review and meta-analysis, Inflamm Bowel Dis, 20, 1, 10.1097/01.MIB.0000436951.80898.6d · DOI · Paper page
  49. Fradkin, 2010, Recombinant murine growth hormone from E. coli inclusion bodies: expression, high-pressure solubilization and refolding, and characterization of activity and structure, Biotechnol Prog, 26, 743, 10.1002/btpr.393 · DOI
  50. Patton, 2005, An acid dissociation bridging ELISA for detection of antibodies directed against therapeutic proteins in the presence of antigen, J Immunol Methods, 304, 189, 10.1016/j.jim.2005.06.014 · DOI · Paper page
  51. Frey, 1998, A statistically defined endpoint titer determination method for immunoassays, J Immunol Methods, 221, 35, 10.1016/S0022-1759(98)00170-7 · DOI · Paper page
  52. Malyala, 2008, Endotoxin limits in formulations for preclinical research, J Pharm Sci, 97, 2041, 10.1002/jps.21152 · DOI · Paper page
  53. Ross, 2000, Immunogenicity of interferon-β in multiple sclerosis patients: influence of preparation, dosage, dose frequency, and route of administration, Ann Neurol, 48, 706, 10.1002/1531-8249(200011)48:5<706::AID-ANA3>3.0.CO;2-V · DOI
  54. Kijanka, 2013, Effect of treatment regimen on the immunogenicity of human interferon beta in immune tolerant mice, Pharm Res, 30, 1553, 10.1007/s11095-013-0992-9 · DOI
  55. Gupta, 1998, Aluminum compounds as vaccine adjuvants, Adv Drug Deliv Rev, 32, 155, 10.1016/S0169-409X(98)00008-8 · DOI · Paper page
  56. Romero Méndez, 2007, Potentiation of the immune response to non-adsorbed antigens by aluminum-containing adjuvants, Vaccine, 25, 825, 10.1016/j.vaccine.2006.09.039 · DOI
  57. Clausi, 2008, Influence of particle size and antigen binding on effectiveness of aluminum salt adjuvants in a model lysozyme vaccine, J Pharm Sci, 97, 5252, 10.1002/jps.21390 · doi:10.1002/jps.21390
  58. Snapper, 1992, Induction of IgG3 secretion by interferon gamma: a model for T cell-independent class switching in response to T cell-independent type 2 antigens, J Exp Med, 175, 1367, 10.1084/jem.175.5.1367 · DOI · Paper page
  59. Coutelier, 1987, IgG2a restriction of murine antibodies elicited by viral infections, J Exp Med, 165, 64, 10.1084/jem.165.1.64 · DOI · Paper page
  60. Nimmerjahn, 2005, Divergent immunoglobulin G subclass activity through selective Fc receptor binding, Science, 310, 1510, 10.1126/science.1118948 · DOI · Paper page

Cited by

See all 40

Metadata

Authors
Chisholm, C. F., Baker, A. E., Soucie, K. R., Torres, R. M., Carpenter, J. F., & Randolph, T. W.
Venue
Journal of Pharmaceutical Sciences
Publisher
Elsevier BV
Published
2016-05
Volume
105
Issue
5
Pages
1623-1632
ISSN
0022-3549 (ISSN-L)
OpenAlex
W2309101429
Cited by
40
References
4
FWCI
1.18
Type
journal article
Language
en
Open access
bronze
Licence
Funders
  • NIH (ROI EB006006)
  • FDA Office of Women’s Health
  • U.S. Food and Drug Administration
  • Oak Ridge Institute for Science and Education
  • U.S. Department of Energy
  • FDA/Center

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Silicone Oil Microdroplets Can Induce Antibody Responses Against Recombinant Murine Growth Hormone in Mice. https://app.cochat.ai/papers/10.1016/j.xphs.2016.02.019
The paper
Chisholm, C. F., Baker, A. E., Soucie, K. R., Torres, R. M., Carpenter, J. F., & Randolph, T. W. (2016). Silicone Oil Microdroplets Can Induce Antibody Responses Against Recombinant Murine Growth Hormone in Mice. Journal of Pharmaceutical Sciences. https://doi.org/10.1016/j.xphs.2016.02.019

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.